CurrentUnitedHealthcarePolicy N/A

Prior authorization criteria for biologic or targeted therapy for systemic lupus erythematosus (SLE)

Prior authorization form and criteria for prescribing a specified medication for beneficiaries with active systemic lupus erythematosus (SLE), including lupus nephritis and CNS lupus; applies to prescribers requesting coverage through UnitedHealthcare.

Policy Summary

PayerUnitedHealthcare

PolicyPrior authorization criteria for biologic or targeted therapy for systemic lupus erythematosus (SLE)

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionComplete the authorization form questions 1–7 and attach progress notes demonstrating diagnosis, specialist involvement, concomitant therapies, and clinical response as required.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

8authorization form questions for initial and re-authorization

365max therapy length (days)

1pharmacy PA call center

Coverage Criteria

Initial authorization

Covered when ALL of the following are met (as documented on the form):

Initial authorization criteria: 1) Beneficiary has a diagnosis of active systemic lupus erythematosus (SLE). 2) Indicate whether beneficiary has lupus nephritis. 3) Medication is prescribed by or in consultation with a rheumatologist. 4) Beneficiary is auto-antibody positive. 5) Medication is used in combination with standard treatment regimens (NSAIDs, corticosteroids, anti-malarials, or immunosuppressive drugs) or those regimens were not tolerated or were not beneficial. 6) Beneficiary has severe active lupus nephritis or severe active central nervous system lupus, if applicable. 7) Indicate whether the medication is being used concurrently with other biologics and/or IV cyclophosphamide.

Answers to questions 1–7 must be completed on the form; drug name, strength, quantity per 30 days, and requested length of therapy must be provided (length of therapy options listed up to 365 days).

Re-authorization

Re-authorization covered when ALL of the following are met:

Re-authorization criteria: 8) Documented improvement in functional impairment, such as fewer steroid-requiring flares, lower average daily oral prednisone dose, improved daily function measured by a validated scale or clinic documentation, or sustained improvement in laboratory measures of lupus activity.

Policy Summary

PayerUnitedHealthcare

PolicyPrior authorization criteria for biologic or targeted therapy for systemic lupus erythematosus (SLE)

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionComplete the authorization form questions 1–7 and attach progress notes demonstrating diagnosis, specialist involvement, concomitant therapies, and clinical response as required.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

The form requires specific documentation to demonstrate medical necessity. For initial authorization, the prescriber must complete questions 1–7 including auto‑antibody status, use with or intolerance to standard therapies (NSAIDs, corticosteroids, anti‑malarials, or immunosuppressives), severity of lupus nephritis or CNS lupus, and concurrent biologic or IV cyclophosphamide use. For re‑authorization, the form requires answer to question 8 documenting clinical improvement (for example, fewer steroid‑requiring flares, lower average daily prednisone dose, improved function by validated scale or clinic documentation, or sustained improvement in laboratory measures) and attachment of current progress notes. The prescriber’s signature and date are mandatory on re‑authorization submissions.

Provider Actions and Requirements

Prior Authorization

Authorization form completion required

Prior authorization requires completion of the initial authorization questions (1–7) confirming diagnosis (active SLE, lupus nephritis), specialist involvement, antibody status, concomitant therapies, and severity indicators.

Complete questions 1–7 on the initial authorization form
Confirm diagnosis of active systemic lupus erythematosus (SLE) or lupus nephritis
Indicate rheumatologist involvement (prescribing or consultation)

Step Therapy

Concomitant or prior standard therapies

Provider must indicate whether the beneficiary is using the medication in combination with standard treatment regimens (NSAIDs, corticosteroids, anti-malarials, or immunosuppressive drugs) or whether these treatments were not tolerated or not beneficial. This is required information for initial authorization.

Document current or prior use of NSAIDs, corticosteroids, anti-malarials, or immunosuppressants
If standard therapies were not tolerated or ineffective, indicate reason
Question 5 on the initial authorization form must be answered

Documentation Required

Required documentation

Attach current progress notes and include the prescriber signature and date on the form. Re-authorization requires documentation of clinical improvement.

Attach current progress notes documenting disease status and clinical response
Prescriber signature and date are mandatory on the form
For re-authorization, answer question 8 and provide evidence of improvement (fewer steroid-requiring flares, lower prednisone dose, validated functional scale improvement, improved daily performance, or sustained laboratory improvement)

Denial Risk

Potential denial triggers

Missing or incomplete answers—especially absence of diagnosis of active SLE or lupus nephritis, lack of rheumatologist involvement, or no documentation of concomitant/ prior standard therapies—may result in denial of the request.

Incomplete initial authorization questions (1–7) may trigger denial
No documentation of concomitant or prior standard therapies (or intolerance) is a denial risk
Lack of prescriber signature or missing progress notes may result in denial

Definitions

Active systemic lupus erythematosus (SLE)

DefinitionActive systemic lupus erythematosus (SLE) — form asks whether the beneficiary has a diagnosis of active SLE (question 1 on initial authorization).

How it is confirmed on the formAnswered explicitly on the initial authorization form: 'Does the beneficiary have a diagnosis of active systemic lupus erythematosus (SLE)?' with Yes/No checkboxes (question 1).

Required for initial approvalCompletion of this question (Q1) is required as part of the initial authorization packet; missing or negative answer may trigger denial.

Related form itemsUsed together with specialist involvement (Q3), auto-antibody status (Q4), concomitant/previous therapies (Q5), and severity questions (Q2/Q6) to determine coverage.

Severe active lupus nephritis or CNS lupus

DefinitionSevere active lupus nephritis or severe active central nervous system (CNS) lupus — form asks whether the beneficiary has this organ‑threatening disease (question 6).

How it is captured on the formQuestion 6 on the initial authorization: 'Does the beneficiary have a diagnosis of severe active lupus nephritis or severe active central nervous system lupus?' with Yes/No checkboxes.

Role in coverage decisionA positive response identifies organ‑threatening disease and is one of the required initial authorization criteria collected on the form.

Associated itemsConsidered alongside lupus nephritis presence (Q2), specialist involvement (Q3), and concurrent biologic/IV cyclophosphamide use (Q7).

OpenPayer

Prior authorization criteria for biologic or targeted therapy for systemic lupus erythematosus (SLE)

Coverage Criteria

Provider Actions and Requirements

Background

Definitions